The number of orphan drugs, i.e. drugs for rare diseases, is vastly growing. These drugs are often associated with high drug prices. Cost-effectiveness studies… Read more »
Tim Kanters (PhD) works as a researcher at the institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands. His PhD dissertation was on health technology assessment of orphan drugs, with a particular focus on health economics aspects of ERT in Pompe disease.
Latest posts by Tim Kanters (see all)
- Cost-effectiveness of ERT in adult patients with Pompe disease - 19th December 2017